But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of ...

reported an increase in sales of Lixiana, direct oral anticoagulant; Tarlige, pain treatment; and Enhertu, anti-cancer agent; as well as the sales of Daiichi Sankyo Healthcare. A gain on ...

High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in ...

Daiichi Sankyo’s optimism is driven by the strong performance of Enhertu, with related revenue soaring by 45% YoY to ¥651 billion, accounting for the majority of the company’s overall revenue increase ...